The seventh meeting of the Informal Drug Policy Dialogues in Latin America took place in Montevideo. And centered on the following issues: Micro-trafficking and proportionality of sentences; Challenges to reforming drug policies; Marijuana in Latin America; and Options and debates in international and regional organizations.
The seventh meeting of the Informal Drug Policy Dialogues in Latin America took place in Montevideo, Uruguay. The first Informal Dialogue also took place in Montevideo in September 2007. The meeting was supported by Uruguay’s National Drug Board (Junta Nacional de Drogas, or JND). The two days of dialogue were divided into four sessions that centered on the following issues: (1) Micro-trafficking and proportionality of sentences; (2) Challenges to reforming drug policies; (3) Marijuana in Latin America: Has the time come to open the debate?; and (4) Options and debates in international and regional organizations. There was also a discussion on the impact of the decriminalization of drug consumption in Portugal.
The eighth meeting of the Informal Drug Policy Dialogue series took place in Lisbon on January 21-22, 2011, a joint initiative of Transnational Institute (TNI) and Diogenis, Drug Policy Dialogue in South East Europe that has replaced the Andreas Papandreou Foundation (APF) in co-operation with the Portuguese Institute on Drugs and Drug Addiction (IDT). Over 50 policy makers, practitioners, academics, and representatives from NGOs and governmental organisations attended the meeting, and discussed the Portuguese decriminalisation model, cannabis policy reform, and the agenda and global initiatives at the 54th Session of the Commission on Narcotic Drugs.
Prior to the Dialogue an Expert Seminar on Threshold Quantities was held in cooperation with the European Monitoring Centre on Drugs and Drugs Addiction (EMCDDA). The issues under discussion were the advantages and disadvantages of threshold quantities as a policy and legislative tool and it was hoped that this seminar would provide a springboard to inform current debate and to assist the elaboration of evidence-based drug law reform proposals now and in the future.